Cargando…

Exploring the biological functional mechanism of the HMGB1/TLR4/MD-2 complex by surface plasmon resonance

BACKGROUND: High Mobility Group Box 1 (HMGB1) was first identified as a nonhistone chromatin-binding protein that functions as a pro-inflammatory cytokine and a Damage-Associated Molecular Pattern molecule when released from necrotic cells or activated leukocytes. HMGB1 consists of two structurally...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Mingzhu, Bianchi, Marco E., Coleman, Tom R., Tracey, Kevin J., Al-Abed, Yousef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6085627/
https://www.ncbi.nlm.nih.gov/pubmed/30134799
http://dx.doi.org/10.1186/s10020-018-0023-8
_version_ 1783346371008397312
author He, Mingzhu
Bianchi, Marco E.
Coleman, Tom R.
Tracey, Kevin J.
Al-Abed, Yousef
author_facet He, Mingzhu
Bianchi, Marco E.
Coleman, Tom R.
Tracey, Kevin J.
Al-Abed, Yousef
author_sort He, Mingzhu
collection PubMed
description BACKGROUND: High Mobility Group Box 1 (HMGB1) was first identified as a nonhistone chromatin-binding protein that functions as a pro-inflammatory cytokine and a Damage-Associated Molecular Pattern molecule when released from necrotic cells or activated leukocytes. HMGB1 consists of two structurally similar HMG boxes that comprise the pro-inflammatory (B-box) and the anti-inflammatory (A-box) domains. Paradoxically, the A-box also contains the epitope for the well-characterized anti-HMGB1 monoclonal antibody “2G7”, which also potently inhibits HMGB1-mediated inflammation in a wide variety of in vivo models. The molecular mechanisms through which the A-box domain inhibits the inflammatory activity of HMGB1 and 2G7 exerts anti-inflammatory activity after binding the A-box domain have been a mystery. Recently, we demonstrated that: 1) the TLR4/MD-2 receptor is required for HMGB1-mediated cytokine production and 2) the HMGB1–TLR4/MD-2 interaction is controlled by the redox state of HMGB1 isoforms. METHODS: We investigated the interactions of HMGB1 isoforms (redox state) or HMGB1 fragments (A- and B-box) with TLR4/MD-2 complex using Surface Plasmon Resonance (SPR) studies. RESULTS: Our results demonstrate that: 1) intact HMGB1 binds to TLR4 via the A-box domain with high affinity but an appreciable dissociation rate; 2) intact HMGB1 binds to MD-2 via the B-box domain with low affinity but a very slow dissociation rate; and 3) HMGB1 A-box domain alone binds to TLR4 more stably than the intact protein and thereby antagonizes HMGB1 by blocking HMGB1 from interacting with the TLR4/MD-2 complex. CONCLUSIONS: These findings not only suggest a model whereby HMGB1 interacts with TLR4/MD-2 in a two-stage process but also explain how the A-box domain and 2G7 inhibit HMGB1. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s10020-018-0023-8) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6085627
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-60856272018-08-16 Exploring the biological functional mechanism of the HMGB1/TLR4/MD-2 complex by surface plasmon resonance He, Mingzhu Bianchi, Marco E. Coleman, Tom R. Tracey, Kevin J. Al-Abed, Yousef Mol Med Research Article BACKGROUND: High Mobility Group Box 1 (HMGB1) was first identified as a nonhistone chromatin-binding protein that functions as a pro-inflammatory cytokine and a Damage-Associated Molecular Pattern molecule when released from necrotic cells or activated leukocytes. HMGB1 consists of two structurally similar HMG boxes that comprise the pro-inflammatory (B-box) and the anti-inflammatory (A-box) domains. Paradoxically, the A-box also contains the epitope for the well-characterized anti-HMGB1 monoclonal antibody “2G7”, which also potently inhibits HMGB1-mediated inflammation in a wide variety of in vivo models. The molecular mechanisms through which the A-box domain inhibits the inflammatory activity of HMGB1 and 2G7 exerts anti-inflammatory activity after binding the A-box domain have been a mystery. Recently, we demonstrated that: 1) the TLR4/MD-2 receptor is required for HMGB1-mediated cytokine production and 2) the HMGB1–TLR4/MD-2 interaction is controlled by the redox state of HMGB1 isoforms. METHODS: We investigated the interactions of HMGB1 isoforms (redox state) or HMGB1 fragments (A- and B-box) with TLR4/MD-2 complex using Surface Plasmon Resonance (SPR) studies. RESULTS: Our results demonstrate that: 1) intact HMGB1 binds to TLR4 via the A-box domain with high affinity but an appreciable dissociation rate; 2) intact HMGB1 binds to MD-2 via the B-box domain with low affinity but a very slow dissociation rate; and 3) HMGB1 A-box domain alone binds to TLR4 more stably than the intact protein and thereby antagonizes HMGB1 by blocking HMGB1 from interacting with the TLR4/MD-2 complex. CONCLUSIONS: These findings not only suggest a model whereby HMGB1 interacts with TLR4/MD-2 in a two-stage process but also explain how the A-box domain and 2G7 inhibit HMGB1. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s10020-018-0023-8) contains supplementary material, which is available to authorized users. BioMed Central 2018-05-10 /pmc/articles/PMC6085627/ /pubmed/30134799 http://dx.doi.org/10.1186/s10020-018-0023-8 Text en © The Author(s) 2018, corrected publication June/2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
He, Mingzhu
Bianchi, Marco E.
Coleman, Tom R.
Tracey, Kevin J.
Al-Abed, Yousef
Exploring the biological functional mechanism of the HMGB1/TLR4/MD-2 complex by surface plasmon resonance
title Exploring the biological functional mechanism of the HMGB1/TLR4/MD-2 complex by surface plasmon resonance
title_full Exploring the biological functional mechanism of the HMGB1/TLR4/MD-2 complex by surface plasmon resonance
title_fullStr Exploring the biological functional mechanism of the HMGB1/TLR4/MD-2 complex by surface plasmon resonance
title_full_unstemmed Exploring the biological functional mechanism of the HMGB1/TLR4/MD-2 complex by surface plasmon resonance
title_short Exploring the biological functional mechanism of the HMGB1/TLR4/MD-2 complex by surface plasmon resonance
title_sort exploring the biological functional mechanism of the hmgb1/tlr4/md-2 complex by surface plasmon resonance
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6085627/
https://www.ncbi.nlm.nih.gov/pubmed/30134799
http://dx.doi.org/10.1186/s10020-018-0023-8
work_keys_str_mv AT hemingzhu exploringthebiologicalfunctionalmechanismofthehmgb1tlr4md2complexbysurfaceplasmonresonance
AT bianchimarcoe exploringthebiologicalfunctionalmechanismofthehmgb1tlr4md2complexbysurfaceplasmonresonance
AT colemantomr exploringthebiologicalfunctionalmechanismofthehmgb1tlr4md2complexbysurfaceplasmonresonance
AT traceykevinj exploringthebiologicalfunctionalmechanismofthehmgb1tlr4md2complexbysurfaceplasmonresonance
AT alabedyousef exploringthebiologicalfunctionalmechanismofthehmgb1tlr4md2complexbysurfaceplasmonresonance